First Time Loading...

Atara Biotherapeutics Inc
NASDAQ:ATRA

Watchlist Manager
Atara Biotherapeutics Inc Logo
Atara Biotherapeutics Inc
NASDAQ:ATRA
Watchlist
Price: 0.7147 USD -0.54%
Updated: Apr 25, 2024

Gross Margin
Atara Biotherapeutics Inc

-3.7%
Current
-4%
Average
61.9%
Industry
Negative for the last year
-3.7%
Negative average
-4%
Better than average
Worse than industry value

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
-3.7%
=
Gross Profit
-313k
/
Revenue
8.6m

Gross Margin Across Competitors

Gross Margin Comparison
Atara Biotherapeutics Inc Competitors

Country Company Market Cap Gross
Margin
US
Atara Biotherapeutics Inc
NASDAQ:ATRA
76.1m USD
-4%
US
Abbvie Inc
NYSE:ABBV
295.7B USD
66%
US
Amgen Inc
NASDAQ:AMGN
143.7B USD
70%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.5B USD
87%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
97.6B USD
86%
AU
CSL Ltd
ASX:CSL
134.5B AUD
52%
US
Gilead Sciences Inc
NASDAQ:GILD
81.5B USD
78%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
75%
US
Moderna Inc
NASDAQ:MRNA
40.1B USD
31%
US
Biogen Inc
NASDAQ:BIIB
28.9B USD
74%
KR
Celltrion Inc
KRX:068270
36.8T KRW
48%
Atara Biotherapeutics Inc
NASDAQ:ATRA
Country US
Market Cap 76.1m USD
Gross Margin
-4%
Abbvie Inc
NYSE:ABBV
Country US
Market Cap 295.7B USD
Gross Margin
66%
Amgen Inc
NASDAQ:AMGN
Country US
Market Cap 143.7B USD
Gross Margin
70%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Country US
Market Cap 102.5B USD
Gross Margin
87%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Country US
Market Cap 97.6B USD
Gross Margin
86%
CSL Ltd
ASX:CSL
Country AU
Market Cap 134.5B AUD
Gross Margin
52%
Gilead Sciences Inc
NASDAQ:GILD
Country US
Market Cap 81.5B USD
Gross Margin
78%
Seagen Inc
NASDAQ:SGEN
Country US
Market Cap 43.1B USD
Gross Margin
75%
Moderna Inc
NASDAQ:MRNA
Country US
Market Cap 40.1B USD
Gross Margin
31%
Biogen Inc
NASDAQ:BIIB
Country US
Market Cap 28.9B USD
Gross Margin
74%
Celltrion Inc
KRX:068270
Country KR
Market Cap 36.8T KRW
Gross Margin
48%

Profitability Report

View the profitability report to see the full profitability analysis for Atara Biotherapeutics Inc.

Full Profitability Report

See Also

Summary
ATRA intrinsic value, competitors valuation, and company profile.
DCF Valuation
ATRA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ATRA stock valuation using valuation multiples.
Wall Street Estimates
ATRA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ATRA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
-3.7%
=
Gross Profit
-313k
/
Revenue
8.6m
What is the Gross Margin of Atara Biotherapeutics Inc?

Based on Atara Biotherapeutics Inc's most recent financial statements, the company has Gross Margin of -3.7%.

ALPHA SPREAD
Join more than 131,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.